Search Videos and More

Showing 13 - 24 of 183 results

Previous| 1 | 2 | 3 ...16 |Next


Paper Proposes New Community-Oriented Fellowship Training Model for Hematologists/Oncologists News

Paper Proposes New Community-Oriented Fellowship Training Model for Hematologists/Oncologists

As patients with cancer increasingly receive treatment in community hospitals and clinics and many such centers experience a shortage of oncologists, a group of physicians at Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, and Harvard Medical School has proposed the first-ever training blueprint for oncologists planning careers in a community or academic-community setting.
Study Finds That Risk of Adverse Side Effects From Cancer Immunotherapy is Higher in Patients with Certain Inherited Genetic Variations News

Study Finds That Risk of Adverse Side Effects From Cancer Immunotherapy is Higher in Patients with Certain Inherited Genetic Variations

Even as they've revolutionized cancer treatment, drugs known as immune checkpoint inhibitors can produce a range of adverse, immune-related side effects. In a new study, scientists at Dana-Farber Cancer Institute identify, for the first time, inherited genetic variations that place patients at high risk for these complications.
Dana-Farber Research Publication 12.15.2021 News

Dana-Farber Research Publication 12.15.2021

This twice-monthly newsletter highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors.
Next-Generation Drug Improves Progression-Free Survival in Relapsed Chronic Lymphocytic Leukemia News

Next-Generation Drug Improves Progression-Free Survival in Relapsed Chronic Lymphocytic Leukemia

A head-to-head clinical trial in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) has found that zanubrutinib, a next-generation BTK inhibitor, was more effective at preventing disease progression and better tolerated than ibrutinib, the first-generation BTK inhibitor that is the current standard treatment in that setting.
New Clinical Tool for Clonal Hematopoiesis Identifies Patients at High Risk for Blood Cancer News

New Clinical Tool for Clonal Hematopoiesis Identifies Patients at High Risk for Blood Cancer

Clonal hematopoiesis (CH) is a recently characterized condition in which the genetic mutations associated with leukemia and other blood cancers are found in the blood of individuals without cancer. This pre-cancerous state is fairly common — for example, it’s present in roughly 15% of people over age 65 — but only a small percentage, around 4%, will go on to develop blood cancer.
News

CAR-T-Cell Shows Promise in Patients with Lymphoma of the Brain and Spinal Cord in Early Trial

A CAR-T-cell therapy known as axicabtagene ciloleucel (axi-cel) is safe and shows encouraging signs of efficacy in a small pilot trial involving patients with lymphoma of the brain and/or spinal cord, Dana-Farber Cancer Institute investigators report at the 64th American Society of Hematology (ASH) Annual Meeting.
Scientists Map Genetic Evolution of Chronic Lymphocytic Leukemia to Richter's Syndrome News

Scientists Map Genetic Evolution of Chronic Lymphocytic Leukemia to Richter's Syndrome

Every year, up to 1% of patients with chronic lymphocytic leukemia (CLL), a slow-growing blood cancer, have their disease transform into a far more aggressive cancer, a form of lymphoma known as Richter's Syndrome. For the most part, the genomic changes that underlie this metamorphosis and push it forward have been obscure, hindering advances in treatment.
ASH Preview News

ASH Preview

Dana-Farber physician-scientists will share research and clinical advances at the 2022 Annual Meeting of the American Society of Hematology (ASH) December 10-13.
San Antonio Breast Cancer Symposium (SABCS): December 2022 Symposium

San Antonio Breast Cancer Symposium (SABCS): December 2022

The 45th annual San Antonio Breast Cancer Symposium. December 6 - 10, 2022
Breast Oncology Research Presentations Schedule Document

Breast Oncology Research Presentations Schedule

The 45th annual San Antonio Breast Cancer Symposium. December 6 - 10, 2022
Dana-Farber Research Publication 12.1.2021 News

Dana-Farber Research Publication 12.1.2021

This twice-monthly newsletter highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors.
New International Partnership to Accelerate Search for Cancer Cures News

New International Partnership to Accelerate Search for Cancer Cures

Cancer patients in Australia and the United States will benefit from a new research-focused collaboration between the Peter MacCallum Cancer Centre and Dana-Farber Cancer Institute in Boston.

Showing 13 - 24 of 183 results

Previous| 1 | 2 | 3 ...16 |Next